Literature DB >> 24956553

Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.

Zong-ying Liu1, Tanja Wenzler2, Reto Brun2, Xiaohua Zhu3, David W Boykin4.   

Abstract

Fifteen novel bis-arylimidamide derivatives with various 6-membered (7a-c) and 5-membered (7d-o) heterocyclic rings replacing the terminal pyridyl rings of the lead compound DB766{(2,5-bis[2-i-propoxy-4-(2-pyridylimino)aminophenylfuran]}, were prepared and evaluated versus Trypanosoma cruzi, Leishmania amazonensis, Trypanosoma brucei rhodesiense and Plasmodium falciparum. Compound 7a with pyrimidine replacing the pyridine rings showed good activity versus T. cruzi, T. brucei rhodesiense and P. falciparum (IC50 = 200 nM, 32 nM and 8.5 nM, respectively). Three compounds (7g, 7i, 7j) with thiazole replacing the pyridine rings gave low micromolar (0.17-0.3 μM) IC50 values versus L. amazonensis, however only 7g exhibited an acceptable selectivity index (SI = 27). Compounds 7a, 7j and 7m exhibited potent activity against T. brucei rhodesiense (IC50 = 12-60 nM). Ten of the 15 compounds with pyrimidine, pyrrole, thiazole and imidazole terminal units were highly active against P. falciparum (IC50 = 9-87 nM). Both pyrimidine and pyridine terminal groups are advantageous for anti-T. cruzi activity and several different heterocyclic terminal units are effective versus P. falciparum, both findings merit further investigation.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antiparasitic agents; Bis-arylimidamides; DB766

Mesh:

Substances:

Year:  2014        PMID: 24956553     DOI: 10.1016/j.ejmech.2014.06.022

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

Review 1.  An Overview of the Synthesis and Antimicrobial, Antiprotozoal, and Antitumor Activity of Thiazole and Bisthiazole Derivatives.

Authors:  Anca-Maria Borcea; Ioana Ionuț; Ovidiu Crișan; Ovidiu Oniga
Journal:  Molecules       Date:  2021-01-25       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.